Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Gardiner
R A
RA
Nicol
D L
DL
Green
H J
HJ
Yaxley
J
J
Watson
R
R
Mactaggart
P
P
Headley
B C
BC
Swanson
C
C
Pakenham
K I
KI
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000627:therapeutic use*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D008297:Male; D009483:Neuropsychological Tests; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D005485:Flutamide; C053541:bicalutamide; D016729:Leuprolide